GPR

GW 9508 is a cell-permeable aminophenylpropanoate that acts as a potent and selective agonist for the G-protein coupled receptor (GPCR) GRP40/FFA1 receptor (EC50 ?50 nM) with reduced activity towards family members GRP120 (EC50 ?3.5 μM), GRP41/GRP43 (EC50 >50 μM), as well as a panel of eight other free fatty acid (FFA) and prostaglandin receptors.

Diphenyleneiodonium chloride has been shown to be a potent irreversible inhibitor of NOS2 (iNOS) from macrophages and NOS3 (eNOS) from endothelial cells.

Conoidin A is a cell permeable inhibitor of T. gondii enzyme peroxiredoxin II (TgPrxII).

Ogremorphin is a selective inhibitor of the G protein-coupled receptor GPR68. This compound exhibits notable anti-inflammatory and anti-tumor properties, demonstrating the ability to inhibit the migration of human melanoma cells and induce ferroptosis in glioblastoma cells. Ogremorphin is a valuable tool for researchers investigating the roles of GPR68 in cancer biology and inflammation.

(Rac)-AAA is a potent inhibitor of GPR75, targeting the receptor to modulate key signaling pathways. This compound effectively blocks the downregulation of GPR75 expression induced by 20-HETE, leading to the inhibition of downstream pathways such as EGFR, AKT, NF-κB, and FAK. (Rac)-AAA also reverses 20-HETE-mediated epithelial-mesenchymal transition, characterized by the downregulation of vimentin and upregulation of E-Cadherin, while reducing MMP-2 activity and cancer cell migration. Additionally, it mitigates the upregulation of HIC-5 and affects the localization of PKC-α and phosphorylated AKT, making (Rac)-AAA a significant tool in the study of castration-resistant prostate cancer.

8-Azahypoxanthine is a purine analog that functions as an inhibitor of hypoxanthine-guanine phosphoribosyltransferase (HGPRT). This compound demonstrates antitumor activity, making it a valuable tool in cancer research, particularly for studying adenocarcinoma and other tumor types. Its ability to inhibit HGPRT may provide insights into the mechanisms of tumor growth and potential therapeutic strategies.

Pyrone-211 is a potent agonist of the GPR84 receptor and an inhibitor of AKR1C3. This compound plays a significant role in modulating the expanded polyamine pathway, making it valuable for research in inflammation and metabolic diseases. Its dual functionality as both a receptor agonist and enzyme inhibitor positions Pyrone-211 as a useful tool for exploring cellular signaling and therapeutic interventions in related pathways.

HGPRT/TBrHGPRT1-IN-1 is a selective inhibitor of human hypoxanthine-guanine phosphoribosyltransferase (HGPRT) and Trypanosoma brucei HGPRT1 (TBrHGPRT1), with a Ki value of 3 nM for both targets. This compound effectively reduces cell growth through its targeted inhibition mechanism. HGPRT/TBrHGPRT1-IN-1 is particularly valuable for research applications in the fields of infectious diseases and oncology.

2′-Deoxy-GDP trisodium is a potent inhibitor of hypoxanthine phosphoribosyltransferase (HGPRT), exhibiting an IC50 value of 12.5 μM. As a guanosine monophosphate (GMP) analogue, it plays a significant role in research related to purine metabolism and the recycling pathway in protozoan parasites. This reagent is valuable for studying HGPRT's function and its implications in parasitic diseases.

PSB-CB-27 is a potent and selective inhibitor of the GPR18 receptor with an IC50 of 0.65 μM. It exhibits a high degree of selectivity over human GPR55, CB1, and CB2 receptors. This compound effectively blocks GPR18 activation induced by Δ9-Tetrahydrocannabinol (THC), making it a valuable tool for investigating the roles of GPR18 in inflammatory diseases and cancer immunotherapy research.

GPR88-IN-1 is a selective inhibitor of GPR88, a G protein-coupled receptor involved in modulating dopaminergic signaling. This compound demonstrates potential for investigating the role of GPR88 in various central nervous system disorders, including schizophrenia and drug addiction. It serves as a valuable tool for researchers exploring therapeutic pathways related to neuropsychiatric conditions.

BTI-A-404 is a selective and competitive inverse agonist of the human G protein-coupled receptor GPR43. This compound exhibits potent inhibitory activity, making it valuable for studying mechanisms related to inflammation, obesity, and type 2 diabetes. BTI-A-404 aids in elucidating the role of GPR43 in metabolic disorders and inflammatory responses, providing essential insights for therapeutic development.

AMG 837 hemicalcium is a potent partial agonist targeting the GPR40/FFA1 receptor, demonstrating high oral bioavailability. This compound inhibits [3H]AMG 837 binding at the human FFA1 receptor with a pIC50 value of 8.13. Research indicates that AMG 837 hemicalcium may enhance insulin secretion and help regulate glucose levels in rodent models, making it valuable for studies in metabolic disorders and diabetes research.